Page last updated: 2024-11-13
destruxin e
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
destruxin E: cyclodepsipeptide from entomopathogenic fungus Metarhyzium anisopliae; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 46934590 |
CHEBI ID | 188838 |
MeSH ID | M0120385 |
Synonyms (13)
Synonym |
---|
destruxin e |
destruxin de |
76689-14-0 |
(3r,10s,13s,16s,19s)-16-[(2s)-butan-2-yl]-10,11,14-trimethyl-3-[[(2s)-oxiran-2-yl]methyl]-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone |
CHEBI:188838 |
y168ewu66t , |
e-destruxin |
unii-y168ewu66t |
cyclo(n-methyl-l-alanyl-.beta.-alanyl-4,5-anhydro-3-deoxy-d-erythro-pentonoyl-l-prolyl-l-isoleucyl-n-methyl-l-valyl) |
sb-242539 |
destruxin e, (-)- |
Q27294124 |
GLXC-26433 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" charged radicals (COO-) appear the least toxic probably because they do not penetrate easily the cellular membranes." | ( Insecticidal and cytotoxic effects of natural and hemisynthetic destruxins. Dumas, C; Pais, M; Quiot, JM; Robert, P; Vey, A, 1994) | 0.29 |
" Evaluation of the cytotoxic activity of these different compounds suggested that a wide range of metabolites with synergistic or adverse effects are present in the crude extract." | ( Toxicity testing of destruxins and crude extracts from the insect-pathogenic fungus Metarhizium anisopliae. Butt, TM; Skrobek, A, 2005) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
cyclodepsipeptide | A depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (35)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (2.86) | 18.7374 |
1990's | 14 (40.00) | 18.2507 |
2000's | 11 (31.43) | 29.6817 |
2010's | 9 (25.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (5.56%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 34 (94.44%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |